Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Keluoxin in Treating Non-proliferative Diabetic Retinopathy
CTR20170678Phase 2Completed
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Keluoxin in nonproliferative diabetic retinopathy (NPDR), type 2 diabetes mellitus (T2DM), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Jul 2017; status: completed.
02
Drugs
Keluoxin
03
Conditions
nonproliferative diabetic retinopathy (NPDR)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170678.